Which has higher earnings & valuation, ALMS or ABVX?

Alumis has higher revenue and earnings than Abivax. Abivax is trading at a lower price-to-earnings ratio than Alumis, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Alumis $24.05M 117.37 -$243.32M -$3.86 N/A Abivax N/A N/A -$380.27M -$5.21 N/A

Is ALMS or ABVX more profitable?

Abivax has a net margin of 0.00% compared to Alumis' net margin of -5,933.46%. Alumis' return on equity of -93.15% beat Abivax's return on equity. Company Net Margins Return on Equity Return on Assets Alumis -5,933.46% -93.15% -74.50% Abivax N/A -99.02% -70.26%

Does the media refer more to ALMS or ABVX?

In the previous week, Alumis had 5 more articles in the media than Abivax. MarketBeat recorded 9 mentions for Alumis and 4 mentions for Abivax. Alumis' average media sentiment score of 1.74 beat Abivax's score of 1.24 indicating that Alumis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alumis 8 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Abivax 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor PRAX or ALMS?

In the previous week, Alumis had 5 more articles in the media than Praxis Precision Medicines. MarketBeat recorded 9 mentions for Alumis and 4 mentions for Praxis Precision Medicines. Alumis' average media sentiment score of 1.74 beat Praxis Precision Medicines' score of 1.10 indicating that Alumis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Praxis Precision Medicines 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Alumis 8 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Is KYMR or ALMS more profitable?

Kymera Therapeutics has a net margin of -285.33% compared to Alumis' net margin of -5,933.46%. Kymera Therapeutics' return on equity of -21.22% beat Alumis' return on equity. Company Net Margins Return on Equity Return on Assets Kymera Therapeutics -285.33% -21.22% -19.21% Alumis -5,933.46% -93.15% -74.50%

Does the media refer more to KYMR or ALMS?

In the previous week, Kymera Therapeutics had 12 more articles in the media than Alumis. MarketBeat recorded 21 mentions for Kymera Therapeutics and 9 mentions for Alumis. Alumis' average media sentiment score of 1.74 beat Kymera Therapeutics' score of 1.55 indicating that Alumis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kymera Therapeutics 15 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Alumis 8 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has preferable valuation and earnings, ALMS or KRYS?

Krystal Biotech has higher revenue and earnings than Alumis. Alumis is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Alumis $24.05M 117.37 -$243.32M -$3.86 N/A Krystal Biotech $389.13M 27.34 $204.83M $7.98 45.03

Is ALMS or KRYS more profitable?

Krystal Biotech has a net margin of 54.82% compared to Alumis' net margin of -5,933.46%. Krystal Biotech's return on equity of 19.34% beat Alumis' return on equity. Company Net Margins Return on Equity Return on Assets Alumis -5,933.46% -93.15% -74.50% Krystal Biotech 54.82% 19.34% 17.65%

Does the media favor ALMS or KRYS?

In the previous week, Krystal Biotech had 6 more articles in the media than Alumis. MarketBeat recorded 15 mentions for Krystal Biotech and 9 mentions for Alumis. Alumis' average media sentiment score of 1.74 beat Krystal Biotech's score of 1.70 indicating that Alumis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alumis 8 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Krystal Biotech 14 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Is SMMT or ALMS more profitable?

Summit Therapeutics has a net margin of 0.00% compared to Alumis' net margin of -5,933.46%. Alumis' return on equity of -93.15% beat Summit Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Summit Therapeutics N/A -168.94% -141.92% Alumis -5,933.46% -93.15% -74.50%

Does the media favor SMMT or ALMS?

In the previous week, Summit Therapeutics had 14 more articles in the media than Alumis. MarketBeat recorded 23 mentions for Summit Therapeutics and 9 mentions for Alumis. Alumis' average media sentiment score of 1.74 beat Summit Therapeutics' score of 0.72 indicating that Alumis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Summit Therapeutics 11 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Alumis 8 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Alumis (ALMS) Competitors

$21.81 -0.57 (-2.55%)

As of 04:00 PM Eastern

Compare

ALMS vs. ABVX, PRAX, KYMR, KRYS, and SMMT

Should you buy Alumis stock or one of its competitors? Alumis's main competitors and comparable companies include Abivax (ABVX), Praxis Precision Medicines (PRAX), Kymera Therapeutics (KYMR), Krystal Biotech (KRYS), and Summit Therapeutics (SMMT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Alumis compare to Abivax?

Alumis (NASDAQ:ALMS) and Abivax (NASDAQ:ABVX) are both mid-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, media sentiment, earnings, valuation, institutional ownership, risk and dividends.

Alumis has higher revenue and earnings than Abivax. Abivax is trading at a lower price-to-earnings ratio than Alumis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alumis	$24.05M	117.37	-$243.32M	-$3.86	N/A
Abivax	N/A	N/A	-$380.27M	-$5.21	N/A

Alumis has a beta of -0.69, indicating that its stock price is 169% less volatile than the broader market. Comparatively, Abivax has a beta of 1.03, indicating that its stock price is 3% more volatile than the broader market.

In the previous week, Alumis had 5 more articles in the media than Abivax. MarketBeat recorded 9 mentions for Alumis and 4 mentions for Abivax. Alumis' average media sentiment score of 1.74 beat Abivax's score of 1.24 indicating that Alumis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alumis	8 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Abivax	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Alumis presently has a consensus target price of $40.30, suggesting a potential upside of 84.78%. Abivax has a consensus target price of $156.50, suggesting a potential upside of 40.07%. Given Alumis' higher possible upside, analysts plainly believe Alumis is more favorable than Abivax.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alumis	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75
Abivax	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80

Abivax has a net margin of 0.00% compared to Alumis' net margin of -5,933.46%. Alumis' return on equity of -93.15% beat Abivax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alumis	-5,933.46%	-93.15%	-74.50%
Abivax	N/A	-99.02%	-70.26%

47.9% of Abivax shares are owned by institutional investors. 33.7% of Alumis shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Alumis beats Abivax on 9 of the 15 factors compared between the two stocks.

How does Alumis compare to Praxis Precision Medicines?

Praxis Precision Medicines (NASDAQ:PRAX) and Alumis (NASDAQ:ALMS) are both mid-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, media sentiment, risk, earnings, dividends, valuation, profitability and analyst recommendations.

In the previous week, Alumis had 5 more articles in the media than Praxis Precision Medicines. MarketBeat recorded 9 mentions for Alumis and 4 mentions for Praxis Precision Medicines. Alumis' average media sentiment score of 1.74 beat Praxis Precision Medicines' score of 1.10 indicating that Alumis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Praxis Precision Medicines	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Alumis	8 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Praxis Precision Medicines has a net margin of 0.00% compared to Alumis' net margin of -5,933.46%. Praxis Precision Medicines' return on equity of -34.15% beat Alumis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Praxis Precision Medicines	N/A	-34.15%	-32.42%
Alumis	-5,933.46%	-93.15%	-74.50%

67.8% of Praxis Precision Medicines shares are held by institutional investors. 3.0% of Praxis Precision Medicines shares are held by company insiders. Comparatively, 33.7% of Alumis shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Alumis has higher revenue and earnings than Praxis Precision Medicines. Praxis Precision Medicines is trading at a lower price-to-earnings ratio than Alumis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Praxis Precision Medicines	$8.55M	1,143.90	-$303.27M	-$12.93	N/A
Alumis	$24.05M	117.37	-$243.32M	-$3.86	N/A

Praxis Precision Medicines has a beta of 2.78, meaning that its stock price is 178% more volatile than the broader market. Comparatively, Alumis has a beta of -0.69, meaning that its stock price is 169% less volatile than the broader market.

Praxis Precision Medicines presently has a consensus target price of $585.95, indicating a potential upside of 67.27%. Alumis has a consensus target price of $40.30, indicating a potential upside of 84.78%. Given Alumis' higher possible upside, analysts clearly believe Alumis is more favorable than Praxis Precision Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Praxis Precision Medicines	2 Sell rating(s)	0 Hold rating(s)	16 Buy rating(s)	4 Strong Buy rating(s)	3.00
Alumis	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75

Summary

Praxis Precision Medicines beats Alumis on 9 of the 16 factors compared between the two stocks.

How does Alumis compare to Kymera Therapeutics?

Kymera Therapeutics (NASDAQ:KYMR) and Alumis (NASDAQ:ALMS) are both mid-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, risk, institutional ownership, earnings, analyst recommendations and media sentiment.

Kymera Therapeutics has a beta of 1.95, indicating that its stock price is 95% more volatile than the broader market. Comparatively, Alumis has a beta of -0.69, indicating that its stock price is 169% less volatile than the broader market.

Alumis has lower revenue, but higher earnings than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Alumis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kymera Therapeutics	$39.21M	251.95	-$311.35M	-$3.24	N/A
Alumis	$24.05M	117.37	-$243.32M	-$3.86	N/A

Kymera Therapeutics has a net margin of -285.33% compared to Alumis' net margin of -5,933.46%. Kymera Therapeutics' return on equity of -21.22% beat Alumis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kymera Therapeutics	-285.33%	-21.22%	-19.21%
Alumis	-5,933.46%	-93.15%	-74.50%

Kymera Therapeutics presently has a consensus price target of $128.70, suggesting a potential upside of 8.32%. Alumis has a consensus price target of $40.30, suggesting a potential upside of 84.78%. Given Alumis' higher probable upside, analysts clearly believe Alumis is more favorable than Kymera Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kymera Therapeutics	1 Sell rating(s)	2 Hold rating(s)	20 Buy rating(s)	1 Strong Buy rating(s)	2.88
Alumis	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75

In the previous week, Kymera Therapeutics had 12 more articles in the media than Alumis. MarketBeat recorded 21 mentions for Kymera Therapeutics and 9 mentions for Alumis. Alumis' average media sentiment score of 1.74 beat Kymera Therapeutics' score of 1.55 indicating that Alumis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kymera Therapeutics	15 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Alumis	8 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

Kymera Therapeutics beats Alumis on 10 of the 13 factors compared between the two stocks.

How does Alumis compare to Krystal Biotech?

Alumis (NASDAQ:ALMS) and Krystal Biotech (NASDAQ:KRYS) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, institutional ownership, valuation, analyst recommendations, risk and media sentiment.

Krystal Biotech has higher revenue and earnings than Alumis. Alumis is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alumis	$24.05M	117.37	-$243.32M	-$3.86	N/A
Krystal Biotech	$389.13M	27.34	$204.83M	$7.98	45.03

86.3% of Krystal Biotech shares are owned by institutional investors. 33.7% of Alumis shares are owned by insiders. Comparatively, 13.1% of Krystal Biotech shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Alumis presently has a consensus target price of $40.30, suggesting a potential upside of 84.78%. Krystal Biotech has a consensus target price of $365.40, suggesting a potential upside of 1.68%. Given Alumis' higher possible upside, research analysts plainly believe Alumis is more favorable than Krystal Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alumis	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75
Krystal Biotech	0 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.92

In the previous week, Krystal Biotech had 6 more articles in the media than Alumis. MarketBeat recorded 15 mentions for Krystal Biotech and 9 mentions for Alumis. Alumis' average media sentiment score of 1.74 beat Krystal Biotech's score of 1.70 indicating that Alumis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alumis	8 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Krystal Biotech	14 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Krystal Biotech has a net margin of 54.82% compared to Alumis' net margin of -5,933.46%. Krystal Biotech's return on equity of 19.34% beat Alumis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alumis	-5,933.46%	-93.15%	-74.50%
Krystal Biotech	54.82%	19.34%	17.65%

Alumis has a beta of -0.69, suggesting that its share price is 169% less volatile than the broader market. Comparatively, Krystal Biotech has a beta of 0.53, suggesting that its share price is 47% less volatile than the broader market.

Summary

Krystal Biotech beats Alumis on 11 of the 15 factors compared between the two stocks.

How does Alumis compare to Summit Therapeutics?

Summit Therapeutics (NASDAQ:SMMT) and Alumis (NASDAQ:ALMS) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, earnings, risk, media sentiment and valuation.

Alumis has higher revenue and earnings than Summit Therapeutics. Summit Therapeutics is trading at a lower price-to-earnings ratio than Alumis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Summit Therapeutics	N/A	N/A	-$1.08B	-$1.12	N/A
Alumis	$24.05M	117.37	-$243.32M	-$3.86	N/A

Summit Therapeutics has a beta of -1.23, indicating that its stock price is 223% less volatile than the broader market. Comparatively, Alumis has a beta of -0.69, indicating that its stock price is 169% less volatile than the broader market.

4.6% of Summit Therapeutics shares are held by institutional investors. 83.5% of Summit Therapeutics shares are held by company insiders. Comparatively, 33.7% of Alumis shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, Summit Therapeutics had 14 more articles in the media than Alumis. MarketBeat recorded 23 mentions for Summit Therapeutics and 9 mentions for Alumis. Alumis' average media sentiment score of 1.74 beat Summit Therapeutics' score of 0.72 indicating that Alumis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Summit Therapeutics	11 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Alumis	8 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summit Therapeutics has a net margin of 0.00% compared to Alumis' net margin of -5,933.46%. Alumis' return on equity of -93.15% beat Summit Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Summit Therapeutics	N/A	-168.94%	-141.92%
Alumis	-5,933.46%	-93.15%	-74.50%

Summit Therapeutics currently has a consensus price target of $24.07, suggesting a potential upside of 76.75%. Alumis has a consensus price target of $40.30, suggesting a potential upside of 84.78%. Given Alumis' stronger consensus rating and higher possible upside, analysts clearly believe Alumis is more favorable than Summit Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Summit Therapeutics	1 Sell rating(s)	8 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.44
Alumis	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75

Summary

Alumis beats Summit Therapeutics on 9 of the 14 factors compared between the two stocks.

Get Alumis News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALMS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ALMS vs. The Competition

Export

Metric	Alumis	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.90B	$3.92B	$7.12B	$12.85B
Dividend Yield	N/A	3.61%	2.54%	11.27%
P/E Ratio	N/A	11.69	272.89	25.51
Price / Sales	117.37	1,396.48	686.41	123.12
Price / Cash	N/A	44.06	28.74	36.03
Price / Book	7.57	16.81	11.06	6.34
Net Income	-$243.32M	-$22.71M	$3.47B	$349.45M
7 Day Performance	-5.30%	2.89%	1.28%	-0.10%
1 Month Performance	-22.80%	13.06%	8.29%	4.36%
1 Year Performance	370.04%	55.07%	24.29%	14.91%

Alumis Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ALMS Alumis	3.2115 of 5 stars	$21.81 -2.5%	$40.30 +84.8%	+382.3%	$2.90B	$24.05M	N/A	N/A	Gap Up
ABVX Abivax	2.5023 of 5 stars	$114.95 -2.7%	$156.50 +36.1%	+39.9%	$10.31B	N/A	N/A	61	Positive News
PRAX Praxis Precision Medicines	3.2139 of 5 stars	$375.84 +3.1%	$585.95 +55.9%	+657.0%	$10.18B	$8.55M	N/A	110
KYMR Kymera Therapeutics	1.6789 of 5 stars	$119.80 -1.4%	$125.65 +4.9%	+186.8%	$10.10B	$39.21M	N/A	170	Positive News Analyst Forecast
KRYS Krystal Biotech	2.7479 of 5 stars	$346.58 +2.8%	$365.40 +5.4%	+138.0%	$9.98B	$389.13M	43.43	210	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ALMS) was last updated on 8/31/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Alumis (ALMS) Competitors

ALMS vs. ABVX, PRAX, KYMR, KRYS, and SMMT

How does Alumis compare to Abivax?

Summary

How does Alumis compare to Praxis Precision Medicines?

Summary

How does Alumis compare to Kymera Therapeutics?

Summary

How does Alumis compare to Krystal Biotech?

Summary

How does Alumis compare to Summit Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALMS vs. The Competition

Alumis Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Alumis (ALMS) Competitors

ALMS vs. ABVX, PRAX, KYMR, KRYS, and SMMT

How does Alumis compare to Abivax?

Which has higher earnings & valuation, ALMS or ABVX?

Which has more volatility & risk, ALMS or ABVX?

Does the media refer more to ALMS or ABVX?

Do analysts rate ALMS or ABVX?

Is ALMS or ABVX more profitable?

Do insiders and institutionals have more ownership in ALMS or ABVX?

Summary

How does Alumis compare to Praxis Precision Medicines?

Does the media favor PRAX or ALMS?

Is PRAX or ALMS more profitable?

Do insiders & institutionals have more ownership in PRAX or ALMS?

Which has higher earnings & valuation, PRAX or ALMS?

Which has more volatility and risk, PRAX or ALMS?

Do analysts recommend PRAX or ALMS?

Summary

How does Alumis compare to Kymera Therapeutics?

Which has more volatility & risk, KYMR or ALMS?

Which has higher valuation and earnings, KYMR or ALMS?

Is KYMR or ALMS more profitable?

Do analysts rate KYMR or ALMS?

Does the media refer more to KYMR or ALMS?

Summary

How does Alumis compare to Krystal Biotech?

Which has preferable valuation and earnings, ALMS or KRYS?

Do institutionals & insiders hold more shares of ALMS or KRYS?

Do analysts rate ALMS or KRYS?

Does the media favor ALMS or KRYS?

Is ALMS or KRYS more profitable?

Which has more volatility and risk, ALMS or KRYS?

Summary

How does Alumis compare to Summit Therapeutics?

Which has better earnings & valuation, SMMT or ALMS?

Which has more risk & volatility, SMMT or ALMS?

Do insiders and institutionals have more ownership in SMMT or ALMS?

Does the media favor SMMT or ALMS?

Is SMMT or ALMS more profitable?

Do analysts prefer SMMT or ALMS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALMS vs. The Competition

Alumis Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools